Though the World Health Organization has stopped short of declaring the COVID-19 coronavirus outbreak a pandemic, the virus continues to reach its way around the globe.
The focus has largely been on the immediate public health impact and the toll it’s taken on individuals. But eight weeks in, the outbreak could potentially disrupt the drug supply and business of both major and minor drug manufacturers.
This is because a high percentage of drug ingredients are sourced from China, the epicenter of the coronavirus. This has raised some important intermediate- and long-term strategic business considerations that need to be addressed.